Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 28, 2026, 11:12 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 49 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Remeron (mirtazapine) Clear all
Completed Phase 2 Interventional Results available

Treating Negative Affect in Low Back Pain Patients

NCT04747314
View directory record Official record
Conditions
Chronic Low Back Pain, Negative Affectivity
Interventions
Antidepressant, Enhanced Fear Avoidance Rehabilitation
Drug · Other
Lead sponsor
Ajay Wasan, MD, Msc
Other
Eligibility
18 Years to 75 Years
Enrollment
308 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
3
States / cities
Chestnut Hill, Massachusetts • Rochester, Minnesota • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Sep 28, 2026, 11:12 PM EDT
Withdrawn Phase 1Phase 2 Interventional

Endeavor to Stop Nausea/Vomiting Associated With Pregnancy (E-SNAP)

NCT05452174
View directory record Official record
Conditions
Pregnancy, Severe Nausea and Vomiting, Hyperemesis Gravidarum
Interventions
Mirtazapine
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 49 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 10, 2024 · Synced Sep 28, 2026, 11:12 PM EDT
Completed Phase 2 Interventional Results available

eIMPACT-DM Pilot Trial: Depression Treatment to Reduce Diabetes Risk

NCT04437485
View directory record Official record
Conditions
Depression, Major Depressive Disorder, Dysthymic Disorder, Depressive Symptoms, Type 2 Diabetes, PreDiabetes, Insulin Resistance
Interventions
Good Days Ahead (GDA), Problem Solving Treatment in Primary Care (PST-PC), Antidepressant Medications, Active Control
Behavioral · Drug · Other
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Nov 1, 2023 · Synced Sep 28, 2026, 11:12 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Treatment of Mood and Marriage Study (TOMMS)

NCT00612807
View directory record Official record
Conditions
Major Depressive Disorder, Partner Relational Disorder (V61.10)
Interventions
Weekly marital therapy, As indicated: Sertraline, bupropion, venlafaxine, mirtazepine, nortriptyline, tranylcypromine, lithium augmentation, etc.
Behavioral · Drug
Lead sponsor
Duke University
Other
Eligibility
60 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 23, 2013 · Synced Sep 28, 2026, 11:12 PM EDT
Completed Phase 4 Interventional Results available

Adjunctive Mixed Salts Amphetamine for Depressed Adults With Incomplete Response to Current Antidepressant Therapy

NCT02058693
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
mixed salts amphetamine
Drug
Lead sponsor
Rush University Medical Center
Other
Eligibility
18 Years to 70 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 14, 2023 · Synced Sep 28, 2026, 11:12 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Mirtazapine to Reduce Methamphetamine Use Among MSM With High-risk HIV Behaviors

NCT00497081
View directory record Official record
Conditions
Substance Abuse, HIV Infections
Interventions
mirtazapine, placebo
Drug
Lead sponsor
San Francisco Department of Public Health
Government
Eligibility
18 Years to 60 Years · Male only
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2010
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jan 4, 2015 · Synced Sep 28, 2026, 11:12 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

15 mg Mirtazapine Orally Disintegrating Tablets, Fasting

NCT00835575
View directory record Official record
Conditions
Healthy
Interventions
Mirtazapine 15 mg (Orally Disintegrating) Tablets, REMERON SolTab® 15 mg Orally Disintegrating Tablets
Drug
Lead sponsor
Teva Pharmaceuticals USA
Industry
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Aug 19, 2024 · Synced Sep 28, 2026, 11:12 PM EDT
Terminated Phase 4 Interventional Results available

Nutrition and Pharmacological Algorithm for Oncology Patients Study

NCT04155008
View directory record Official record
Conditions
Oncologic Complications, Quality of Life, Nutrition Poor, Head and Neck Cancer, Lung Cancer, Pancreatic Cancer
Interventions
Dexamethasone, Dronabinol, Mirtazapine, Nutrition Intervention
Drug · Behavioral
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Nov 15, 2022 · Synced Sep 28, 2026, 11:12 PM EDT
Active, not recruiting Phase 2 Interventional

Pilot Study of Mirtazapine for the Dual Tx of Depression and CINV in High-Grade Glioma Pts on TMZ

NCT03935685
View directory record Official record
Conditions
Glioma of Brain
Interventions
Mirtazapine (Remeron)
Drug
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2030
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Sep 23, 2025 · Synced Sep 28, 2026, 11:12 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Efficacy of Mirtazapine in Depressed Cocaine Dependent Subjects

NCT00322309
View directory record Official record
Conditions
Cocaine Dependence, Depression
Interventions
Placebo, Mirtazapine
Other · Drug
Lead sponsor
Boston University
Other
Eligibility
18 Years to 64 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2010
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 19, 2017 · Synced Sep 28, 2026, 11:12 PM EDT
Recruiting Phase 2 Interventional

Clemastine for Improving White Matter and Boosting Antidepressant Response in Late-life Depression

NCT06591091
View directory record Official record
Conditions
Depression
Interventions
Clemastine Fumarate, Placebo
Drug
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
60 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Sep 28, 2026, 11:12 PM EDT
Completed Not applicable Interventional Results available

Effects of Adding Motivational Interviewing to Antidepressant Treatment for Hispanic Adults With Depression

NCT00564278
View directory record Official record
Conditions
Depression
Interventions
Standard antidepressant therapy (SADT), Motivational antidepressant therapy (MADT)
Drug · Behavioral
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 79 Years
Enrollment
217 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 18, 2021 · Synced Sep 28, 2026, 11:12 PM EDT
Completed Phase 4 Interventional Results available

Combining Medications to Enhance Depression Outcomes

NCT00590863
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
SSRI + placebo, Escitalopram + Bupropion SR, Venlafaxine XR + Mirtazapine
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years to 75 Years
Enrollment
665 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
15
States / cities
Tuscaloosa, Alabama • Harbor City, California • Los Angeles, California + 12 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2014 · Synced Sep 28, 2026, 11:12 PM EDT
Completed Phase 2 Interventional Results available

A Study of Quetiapine and Mirtazapine for the Treatment of Alcohol Dependency

NCT01165541
View directory record Official record
Conditions
Alcohol Dependence
Interventions
Mirtazapine, Quetiapine fumarate extended release (Quetiapine XR)
Drug
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years to 64 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
2
States / cities
Bedford, New Hampshire • Hanover, New Hampshire
Source: ClinicalTrials.gov public record
Updated Apr 8, 2018 · Synced Sep 28, 2026, 11:12 PM EDT
Completed Phase 3 Interventional Results available

Mirtazapine Treatment of Anxiety in Children and Adolescents With Pervasive Developmental Disorders

NCT01302964
View directory record Official record
Conditions
Autism Spectrum Disorders
Interventions
Placebo, Mirtazapine
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
5 Years to 17 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
2
States / cities
Indianapolis, Indiana • Lexington, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 6, 2018 · Synced Sep 28, 2026, 11:12 PM EDT
Completed Not applicable Interventional Results available

Study Comparing 3 Different Treatments for Arthritis of the Lower Back (Lumbar Spinal Stenosis)

NCT01943435
View directory record Official record
Conditions
Lumbar Spinal Stenosis
Interventions
NSAIDs; adjunctive analgesics; adjunctive anti-depressants, Lumbar epidural injection, Joint Mobilizations (spine, sacroiliac, hip), Individualized exercises: clinical setting, Group Exercise: community setting
Drug · Procedure · Other
Lead sponsor
Michael Schneider, DC, PhD
Other
Eligibility
60 Years and older
Enrollment
259 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 1, 2018 · Synced Sep 28, 2026, 11:12 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Relative Bioavailability Study of Mirtazapine 15 mg Tablets Under Fasting Conditions

NCT00865696
View directory record Official record
Conditions
Healthy
Interventions
Mirtazapine 15 mg tablets, single dose, REMERON® 15 mg tablets, single dose
Drug
Lead sponsor
Actavis Inc.
Industry
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2001
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Aug 16, 2010 · Synced Sep 28, 2026, 11:12 PM EDT
Terminated Phase 2 Interventional Results available

Phase II Study of Remeron for Cancer Patients Losing More Than 10% of Their Body Weight

NCT00832520
View directory record Official record
Conditions
Advanced Cancer
Interventions
Remeron (mirtazapine)
Drug
Lead sponsor
New Mexico Cancer Research Alliance
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
2
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Apr 9, 2018 · Synced Sep 28, 2026, 11:12 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Effects of Treatment on Decision-making in Major Depression

NCT01916824
View directory record Official record
Conditions
Major Depressive Disorder, Healthy Controls
Interventions
Any FDA Approved Antidepressant
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 65 Years
Enrollment
53 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Nov 20, 2017 · Synced Sep 28, 2026, 11:12 PM EDT
Completed Not applicable Interventional Results available

A Policy Relevant US Trauma Care System Pragmatic Trial for PTSD and Comorbidity

NCT02655354
View directory record Official record
Conditions
Posttraumatic Stress Disorder, Depression, Alcohol-Related Disorders, Suicidal Ideation, Substance-Related Disorders, Mild Cognitive Impairment, Quality of Life, Pain, Wounds and Injury, Brain Injuries, Chronic Disease
Interventions
Motivational Interviewing, Cognitive Behavioral Therapy Elements, Care Management, Fluoxetine, Fluvoxamine, Paroxetine, Sertraline, Citalopram, Venlafaxine, Duloxetine, Mirtazapine, Diphenhydramine, Trazodone, Prazosin
Behavioral · Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
635 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
24
States / cities
Scottsdale, Arizona • Beverly Hills, California • Sacramento, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2021 · Synced Sep 28, 2026, 11:12 PM EDT
Not yet recruiting Not applicable Interventional

Methamphetamine Use Disorder Support in Heart Failure Pilot Study

NCT07211724
View directory record Official record
Conditions
Heart Failure, Methamphetamine Use Disorder
Interventions
MUD Management (contingency management +/- adjunctive MUD pharmacotherapy), HF GDMT management
Other
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
2
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 3, 2026 · Synced Sep 28, 2026, 11:12 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

15 mg Mirtazapine Orally Disintegrating Tablets, Non-Fasting

NCT00834197
View directory record Official record
Conditions
Healthy
Interventions
Mirtazapine 15 mg (Orally Disintegrating) Tablets, REMERON SolTab® 15 mg Orally Disintegrating Tablets
Drug
Lead sponsor
Teva Pharmaceuticals USA
Industry
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Aug 19, 2024 · Synced Sep 28, 2026, 11:12 PM EDT
Completed Phase 4 Interventional

Treatment of Geriatric Bipolar Mood Disorders: A Pilot Study

NCT00177567
View directory record Official record
Conditions
Bipolar Disorder
Interventions
lithium carbonate, Depakote-ER, risperidone, olanzapine, paroxetine, bupropion, lamotrigine, venlafaxine, tranylcypromine, mirtazapine
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
60 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2004
U.S. locations
2
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 14, 2005 · Synced Sep 28, 2026, 11:12 PM EDT
Completed Phase 2Phase 3 Interventional

Treatment of Adolescent Suicide Attempters (TASA)

NCT00080158
View directory record Official record
Conditions
Depression, Suicide, Attempted
Interventions
fluoxetine, sertraline, citalopram, escitalopram, bupropion, mirtazapine, venlafaxine, lithium, Cognitive Behavioral Therapy
Drug · Behavioral
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
12 Years to 18 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
6
States / cities
Baltimore, Maryland • New York, New York • Durham, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 21, 2020 · Synced Sep 28, 2026, 11:12 PM EDT